Medical Pharmacology: Chapter: 26 — Renal Pharmacology -- Module: 1 — Diuretic Pharmacology, Part 1 (Loop Diuretics and Thiazides)

Chapter: 26 — Renal Pharmacology — Module: 1 — Diuretic Pharmacology, Part 1 (Loop Diuretics and Thiazides)
Tier: T3 — Clinical Vignette (11 questions)

1. A 72-year-old woman with hypertension managed on hydrochlorothiazide (HCTZ) 25 mg daily presents to the emergency department after two days of nausea and vomiting from a urinary tract infection. She is alert but confused. Serum sodium is 114 mEq/L, serum osmolality 238 mOsm/kg, and urine osmolality 680 mOsm/kg. Her urine sodium is 42 mEq/L. Which of the following best identifies the pharmacodynamic mechanism responsible for this presentation and the most important initial pharmacological action?

A) HCTZ disrupts the medullary concentration gradient by blocking NKCC2 in the TAL, preventing antidiuretic hormone (ADH) from concentrating the urine; the resulting free water loss has caused severe hypernatremia corrected to hyponatremia by excessive oral fluid intake; the most important initial action is to restrict fluid intake and administer 3% saline to correct the sodium deficit
B) HCTZ blocks NCC in the DCT and impairs urinary dilution while leaving the NKCC2-dependent medullary concentration gradient intact; nausea from the urinary tract infection provided a potent non-osmotic ADH stimulus, and ADH drove water retention into a fully preserved hypertonic medullary interstitium, producing highly concentrated urine (urine osmolality 680 mOsm/kg) and severe hyponatremia; the most important initial pharmacological action is to discontinue HCTZ immediately, as continuing it perpetuates the dilution impairment that prevents free water excretion even as the ADH stimulus is treated
C) HCTZ caused SIADH (syndrome of inappropriate antidiuretic hormone secretion) by directly stimulating hypothalamic ADH synthesis through a pharmacological mechanism independent of osmolality or volume status; the urine osmolality of 680 mOsm/kg reflects this drug-induced ADH excess; the most important initial action is to administer demeclocycline to block ADH action at the collecting duct
D) The hyponatremia reflects furosemide contamination of her HCTZ prescription causing NKCC2 blockade in the TAL; the elevated urine osmolality of 680 mOsm/kg confirms that loop diuretic-induced natriuresis has outpaced free water excretion; the most important initial action is to verify the dispensed medication and switch to a confirmed HCTZ preparation
E) The severe hyponatremia and high urine osmolality reflect primary polydipsia triggered by HCTZ-induced xerostomia (dry mouth); the patient drank excess free water, which was concentrated in the kidney by a normal ADH response to volume expansion; the most important initial action is to restrict water intake and observe without medication change

ANSWER: B

Rationale:

This vignette illustrates the classic thiazide hyponatremia syndrome. The urine osmolality of 680 mOsm/kg in a patient with a serum osmolality of 238 mOsm/kg is the key diagnostic finding: the kidney is producing concentrated urine despite severe hypo-osmolality, demonstrating that ADH is active and the medullary concentration gradient is intact. This is only possible because HCTZ blocks NCC in the DCT — the cortical diluting segment — preventing the generation of dilute urine, while leaving NKCC2 in the TAL untouched and the medullary gradient fully functional. Nausea from the urinary tract infection triggered non-osmotic ADH release, and ADH drove water reabsorption through AQP2 channels into the preserved hypertonic medullary interstitium. The kidney retained free water as concentrated urine rather than excreting it as dilute urine. Elderly women represent the highest-risk demographic for this complication. The most important initial pharmacological action is to discontinue HCTZ immediately: as long as NCC remains blocked, the cortical diluting segment cannot function, the kidney cannot excrete free water regardless of how the ADH stimulus is treated, and the hyponatremia cannot resolve. Fluid restriction, cautious sodium correction guided by the severity of symptoms and rate of sodium decline, and treatment of the underlying UTI are required alongside HCTZ discontinuation.

Option A: Option A is incorrect: HCTZ does not block NKCC2 in the TAL; it blocks NCC in the DCT; HCTZ impairs dilution, not concentration; the presentation is hyponatremia from water retention, not hypernatremia from water loss; administering 3% saline without first addressing the mechanism (HCTZ discontinuation) does not resolve the underlying pharmacodynamic problem.
Option C: Option C is incorrect: HCTZ does not directly stimulate hypothalamic ADH synthesis; the elevated urine osmolality reflects ADH action on an intact medullary gradient, not a drug-induced SIADH state; demeclocycline is an ADH antagonist reserved for chronic SIADH and is not the priority in acute severe hyponatremia.
Option D: Option D is incorrect: the clinical presentation is entirely consistent with HCTZ pharmacodynamics; furosemide contamination is not a rational clinical explanation; loop diuretics impair concentration (not dilution) and would produce a different urine osmolality pattern.
Option E: Option E is incorrect: primary polydipsia produces dilute urine (urine osmolality below plasma osmolality) as the kidney attempts to excrete the water load; a urine osmolality of 680 mOsm/kg is incompatible with primary polydipsia and confirms ADH-driven concentration of a kidney that cannot dilute.

2. A 58-year-old man with heart failure with reduced ejection fraction (HFrEF) and stage 3a CKD (GFR 46 mL/min/1.73 m²) has been stable on furosemide 80 mg daily for six months. He presents with a two-week history of worsening lower extremity edema and decreased urine output. He mentions starting ibuprofen 400 mg three times daily for knee pain approximately twelve days ago. Serum creatinine has risen from 1.4 to 2.2 mg/dL. Potassium and magnesium are within normal limits. Which of the following best identifies the mechanism of his diuretic resistance and AKI, and the single most important first corrective action?

A) Ibuprofen is competing with furosemide for OAT binding sites on the basolateral membrane of the proximal tubule, reducing furosemide secretion into the lumen below the NKCC2 threshold; the most important first corrective action is to switch furosemide to IV administration to bypass OAT competition and restore adequate luminal drug concentration
B) Ibuprofen has induced CYP3A4 in the liver, accelerating furosemide metabolism and reducing its plasma half-life to below the threshold needed for sustained NKCC2 blockade; the most important first corrective action is to double the furosemide dose to compensate for the increased hepatic clearance
C) Ibuprofen raised serum potassium through aldosterone suppression, activating tubuloglomerular feedback that constricts the afferent arteriole; the most important first corrective action is to administer sodium polystyrene sulfonate to lower potassium and relieve the tubuloglomerular feedback-mediated GFR reduction
D) Ibuprofen inhibited renal COX-dependent synthesis of PGE2 and PGI2, removing the prostaglandin-mediated afferent arteriolar dilation that this patient requires to maintain GFR in the setting of reduced cardiac output and CKD; afferent constriction reduced GFR, diminished sodium delivery to NKCC2, and blunted the natriuretic response to furosemide; the most important first corrective action is to stop ibuprofen immediately, as GFR typically begins to recover once prostaglandin synthesis is restored
E) Ibuprofen directly upregulated NKCC2 expression in the TAL through a prostaglandin-independent transcriptional pathway, increasing the sodium reabsorptive capacity of the TAL above the furosemide inhibitory ceiling; the most important first corrective action is to add metolazone for sequential nephron blockade while continuing ibuprofen for analgesia

ANSWER: D

Rationale:

This is a textbook presentation of NSAID-induced diuretic resistance and acute kidney injury (AKI) in a patient whose GFR is prostaglandin-dependent. In patients with HFrEF, reduced cardiac output maximally activates the renin-angiotensin system and sympathetic nervous system, both of which constrict the afferent arteriole and threaten GFR. The kidney compensates by synthesizing PGE2 and PGI2, which dilate the afferent arteriole and maintain GFR against this vasoconstrictive background. In stage 3a CKD, reduced nephron mass further elevates per-nephron prostaglandin dependence. When ibuprofen inhibits COX-1 and COX-2, prostaglandin synthesis is eliminated. The afferent arteriole constricts unopposed, GFR falls from 46 to a level consistent with creatinine rising to 2.2 mg/dL, tubular fluid delivery to NKCC2 decreases, and the natriuretic response to furosemide collapses. The most important first corrective action is to stop ibuprofen immediately: once COX inhibition is removed, prostaglandin synthesis resumes within hours and GFR typically begins to recover, restoring furosemide efficacy without any change to the diuretic regimen. The patient should also be counseled that all NSAIDs — including over-the-counter agents — are contraindicated in his clinical situation.

Option A: Option A is incorrect: while ibuprofen is an organic acid with some OAT affinity, OAT competition is not the primary mechanism of NSAID-induced diuretic resistance; IV furosemide still requires OAT-mediated secretion in the proximal tubule and would not bypass the fundamental problem of reduced GFR from afferent constriction.
Option B: Option B is incorrect: furosemide is not significantly metabolized by CYP3A4; furosemide is predominantly renally eliminated via tubular secretion; ibuprofen does not induce CYP3A4 in a clinically meaningful way for furosemide metabolism.
Option C: Option C is incorrect: potassium is within normal limits, making aldosterone suppression-driven hyperkalemia inconsistent with the clinical picture; tubuloglomerular feedback responds to changes in macula densa sodium and chloride delivery, not to serum potassium changes; this mechanism does not explain the observed creatinine rise and diuretic resistance.
Option E: Option E is incorrect: ibuprofen does not upregulate NKCC2 transcription; no prostaglandin-independent COX-2-mediated pathway for NKCC2 upregulation exists; continuing ibuprofen while adding metolazone would not restore GFR and would further endanger renal function.

3. A 64-year-old woman with newly diagnosed hypertension was started on chlorthalidone 12.5 mg daily six weeks ago. She presents with acute pain, swelling, and erythema of the right first metatarsophalangeal joint. Serum uric acid is 9.8 mg/dL (baseline 5.4 mg/dL). Serum potassium is 3.1 mEq/L, serum magnesium is 1.6 mg/dL, fasting glucose is 108 mg/dL (elevated from baseline 92 mg/dL), and serum calcium is 9.4 mg/dL. Which of the following correctly identifies the mechanism of her hyperuricemia and identifies which of the listed laboratory findings would NOT be expected to result from chlorthalidone's pharmacological mechanism?

A) Chlorthalidone raises serum uric acid through two convergent proximal tubular mechanisms — OAT competition reducing urate secretion and volume contraction-driven URAT1 upregulation increasing urate reabsorption; the serum calcium of 9.4 mg/dL is the laboratory value least likely to represent a direct pharmacological effect of chlorthalidone, because the NCC-blockade-mediated calcium-sparing effect increases tubular calcium reabsorption and reduces urinary calcium, but does not raise serum calcium significantly above the normal range in patients with intact parathyroid function and no pre-existing hypercalcemic disorder
B) Chlorthalidone raises serum uric acid exclusively through volume contraction activating URAT1 in the collecting duct (CD); OAT competition is not a mechanism of thiazide hyperuricemia because thiazides are not secreted via OAT; the potassium of 3.1 mEq/L would NOT be expected because thiazides act only in the DCT and do not increase potassium secretion in the collecting duct
C) Chlorthalidone raises serum uric acid by inhibiting xanthine oxidase in the liver, reducing conversion of xanthine to uric acid and causing uric acid to accumulate through a feedback mechanism; the fasting glucose of 108 mg/dL would NOT be expected because chlorthalidone improves insulin secretion by hyperpolarizing beta-cell membranes through potassium loading
D) Chlorthalidone raises serum uric acid by directly activating purine synthesis in renal tubular cells through an NCC-dependent signaling pathway; the magnesium of 1.6 mg/dL would NOT be expected to be abnormal because chlorthalidone upregulates TRPM6 in the DCT as a compensatory response to NCC blockade, increasing active magnesium reabsorption and protecting against hypomagnesemia
E) Chlorthalidone raises serum uric acid by reducing urinary pH below 5.0, causing uric acid to precipitate in the tubular lumen and be reabsorbed passively rather than excreted; the serum potassium of 3.1 mEq/L would NOT be expected because chlorthalidone acts exclusively on NCC and has no influence on aldosterone or ROMK-mediated potassium secretion in the collecting duct

ANSWER: A

Rationale:

Chlorthalidone raises serum uric acid through two convergent mechanisms in the proximal convoluted tubule (PCT). First, chlorthalidone — like all thiazide-class agents — is an organic anion secreted via OAT1 and OAT3. Urate is also secreted into the tubular lumen through OAT-dependent pathways, and chlorthalidone competes with urate for OAT binding sites, reducing urate secretion and raising serum uric acid. Second, volume contraction from sustained thiazide diuresis activates the renin-angiotensin system, leading to upregulation of URAT1 (SLC22A12) on the apical membrane of PCT cells, which reabsorbs more urate from the lumen back into the blood. Among the listed laboratory values, serum calcium at 9.4 mg/dL (within the normal range) is the one that would NOT be expected to reflect a direct adverse pharmacological effect. The calcium-sparing mechanism of chlorthalidone (NCC blockade → ↓intracellular Na → ↑NCX1 → ↑TRPV5 → ↑calcium reabsorption) reduces urinary calcium and can prevent hypercalciuria-driven stone formation, but in patients with normal parathyroid function, this does not elevate serum calcium above the normal range — the reduced urinary calcium simply reflects more efficient tubular retention. Hypercalcemia from thiazides occurs only in specific settings such as concurrent primary hyperparathyroidism, granulomatous disease, or vitamin D toxicity. The other findings — hypokalemia (3.1 mEq/L), elevated glucose (108 mg/dL), and low-normal magnesium (1.6 mg/dL) — are all pharmacologically expected consequences of thiazide therapy.

Option B: Option B is incorrect: thiazides are secreted via OAT and OAT competition is a well-established mechanism of thiazide hyperuricemia; hypokalemia is an expected finding from volume-mediated secondary aldosteronism upregulating ENaC and ROMK in the collecting duct.
Option C: Option C is incorrect: chlorthalidone does not inhibit xanthine oxidase; xanthine oxidase inhibition is the mechanism of allopurinol; the fasting glucose elevation is pharmacologically expected from thiazide-induced hypokalemia impairing beta-cell insulin secretion.
Option D: Option D is incorrect: chlorthalidone raises serum uric acid through OAT competition and URAT1 upregulation, not through purine synthesis activation; chlorthalidone does not upregulate TRPM6 — thiazides downregulate TRPM6 in the DCT, impairing active magnesium reabsorption and causing hypomagnesemia.
Option E: Option E is incorrect: chlorthalidone does not significantly reduce urinary pH to 5.0 to cause uric acid precipitation as the mechanism of hyperuricemia; hypokalemia is an expected pharmacological consequence of thiazide therapy through volume-mediated aldosterone-ENaC-ROMK activation in the collecting duct.

4. A 55-year-old man with cirrhosis and refractory ascites is on furosemide 120 mg daily and spironolactone 100 mg daily. Despite receiving oral potassium chloride 40 mEq three times daily for five days, his serum potassium remains at 2.8 mEq/L. His serum magnesium is 1.1 mg/dL. He has no diarrhea or vomiting, and his creatinine is stable. A hepatology fellow asks why the potassium is not responding to supplementation. Which of the following best explains the mechanism of refractory hypokalemia and identifies the intervention that must accompany potassium replacement?

A) The refractory hypokalemia reflects furosemide-induced secondary hyperaldosteronism overwhelming the effect of spironolactone; spironolactone must be increased to 200 mg daily to adequately block aldosterone-driven ENaC and ROMK upregulation before potassium supplementation can become effective
B) The refractory hypokalemia is caused by furosemide directly inhibiting Na/K-ATPase on the basolateral membrane of the collecting duct principal cell, preventing intracellular potassium repletion from supplementation; the intervention required is to switch from furosemide to torsemide, which does not inhibit basolateral Na/K-ATPase at therapeutic concentrations
C) Furosemide-induced magnesiuria — from abolition of the TAL lumen-positive potential that normally drives paracellular magnesium reabsorption — has depleted intracellular magnesium in collecting duct principal cells; intracellular magnesium normally blocks ROMK channels, and when depleted, ROMK remains constitutively open and obligatorily secretes potassium into the lumen regardless of systemic potassium levels; potassium replacement cannot normalize serum potassium until magnesium is simultaneously repleted to restore ROMK inhibition
D) The refractory hypokalemia reflects impaired intestinal absorption of oral potassium chloride in cirrhosis due to portal hypertensive enteropathy; switching to intravenous potassium chloride infusion at 20 mEq/hour will bypass the intestinal absorption defect and restore serum potassium without any need to address the magnesium deficit
E) The hypokalemia is refractory because oral potassium chloride is being rapidly excreted in the urine due to high urinary flow from furosemide-driven diuresis; the potassium supplement is reaching the systemic circulation but is excreted before equilibrating with the intracellular compartment; reducing the furosemide dose to eliminate the high urine flow will allow potassium to equilibrate

ANSWER: C

Rationale:

This case illustrates the ROMK disinhibition mechanism that renders hypokalemia refractory to potassium supplementation in the setting of concurrent hypomagnesemia. Under normal physiological conditions, intracellular magnesium (Mg²⁺) acts as a voltage-dependent blocker of ROMK (Kir1.1) channels in the apical membrane of collecting duct principal cells, physically occluding the channel pore and limiting potassium secretion to physiologically appropriate rates. When furosemide blocks NKCC2 in the TAL, it abolishes the lumen-positive transepithelial potential that normally provides the electrochemical driving force for paracellular magnesium reabsorption through claudin-16 and claudin-19 channels in the tight junctions. Magnesium is lost in the urine — as confirmed by this patient's serum magnesium of 1.1 mg/dL — and intracellular magnesium becomes depleted. Without intracellular magnesium to block ROMK channels, they remain constitutively open and potassium secretion into the tubular lumen is obligatory and unregulated. The electrochemical gradient driving potassium out of the cell through open ROMK channels is maintained regardless of how much potassium is administered systemically, because the channel remains open as long as intracellular magnesium is depleted. No amount of oral or intravenous potassium supplementation can normalize serum potassium under these circumstances — it simply exits through persistently open ROMK channels. Magnesium must be repleted concurrently to restore the intracellular magnesium block on ROMK, after which potassium supplementation becomes effective.

Option A: Option A is incorrect: while secondary hyperaldosteronism contributes to hypokalemia in cirrhosis and spironolactone is appropriate, the specific mechanism of potassium refractoriness in this case is ROMK disinhibition from magnesium depletion, not inadequate spironolactone dose; increasing spironolactone without correcting magnesium will not resolve the refractory hypokalemia.
Option B: Option B is incorrect: furosemide does not inhibit basolateral Na/K-ATPase; inhibiting Na/K-ATPase would be acutely cytotoxic; torsemide and furosemide share the same NKCC2-inhibiting mechanism and switching between them would not restore ROMK inhibition.
Option D: Option D is incorrect: while portal hypertensive enteropathy can impair some nutrient absorption, it is not the established explanation for refractory hypokalemia in a patient with documented hypomagnesemia and a clear mechanism; the magnesium-ROMK mechanism is the pharmacologically established explanation that must be addressed.
Option E: Option E is incorrect: potassium excreted in a high urine flow setting still equilibrates with the intracellular compartment before reaching the tubular lumen; the problem is not a transit time issue but constitutively open ROMK channels from magnesium depletion; reducing furosemide may worsen ascites and does not address the ROMK disinhibition mechanism.

5. A 69-year-old man with HFrEF (ejection fraction 28%) presents with acute decompensated heart failure (ADHF). He is on oral furosemide 40 mg daily at home. On admission, the team switches him to IV furosemide 40 mg twice daily. After 24 hours, net urine output is only 400 mL above intake, his weight has not decreased, and he remains dyspneic. Creatinine is stable at 1.3 mg/dL and electrolytes are within normal limits. No NSAIDs or other nephrotoxins are present. A medical student asks what the DOSE trial evidence and the pharmacodynamic principles of loop diuretics indicate should be done next. Which of the following best applies the DOSE trial findings and underlying pharmacodynamic rationale to identify the correct next step?

A) The minimal response confirms that the patient has reached the NKCC2 ceiling for furosemide; the correct next step is to add metolazone 5 mg daily for sequential nephron blockade, which will provide additional natriuresis by blocking distal compensatory sodium reabsorption that is limiting the furosemide response
B) The minimal response reflects tachyphylaxis to furosemide from his chronic outpatient use; the correct next step is to switch to bumetanide 1 mg IV twice daily, as patients who develop tolerance to furosemide retain full sensitivity to bumetanide at equivalent doses
C) The minimal response confirms oral furosemide equivalence has been achieved; the team should maintain IV furosemide 40 mg twice daily for an additional 48 hours before escalating, as the DOSE trial established that clinical response typically occurs on day 2 to 3 of IV therapy and premature dose escalation increases the risk of AKI without additional benefit
D) The minimal response reflects impaired OAT-mediated furosemide secretion from bowel wall edema reducing intestinal blood flow and thereby limiting proximal tubular drug delivery; the correct next step is to switch to continuous IV furosemide infusion at 10 mg/hour to maintain constant luminal drug concentrations above the NKCC2 threshold
E) The current IV dose of 40 mg twice daily equals the home oral daily dose of 40 mg, not the 2.5-times escalation supported by the DOSE (Diuretic Optimization Strategies Evaluation) trial; the DOSE trial demonstrated that high-dose IV furosemide at 2.5 times the total oral daily dose was not inferior to low-dose in renal safety and produced greater net fluid loss and more rapid symptom relief; the correct next step is to escalate to IV furosemide 100 mg twice daily (2.5 × 40 mg = 100 mg per dose), increasing frequency and dosing before considering sequential blockade

ANSWER: E

Rationale:

This vignette requires recognizing that the team has not yet implemented the dosing strategy supported by the DOSE trial evidence. The patient's home oral furosemide dose is 40 mg daily (total daily dose = 40 mg). The DOSE (Diuretic Optimization Strategies Evaluation) trial protocol defined high-dose IV therapy as 2.5 times the total oral daily dose: for this patient, 2.5 × 40 mg = 100 mg per dose (the trial used a twice-daily dosing schedule). The team administered IV furosemide 40 mg twice daily — which equals his daily oral dose divided into two doses, not the 2.5-fold escalation. The DOSE trial demonstrated that high-dose IV furosemide was not inferior to low-dose in worsening renal function (the primary safety concern) while producing significantly greater net fluid loss and more rapid symptom relief, directly supporting dose escalation rather than conservation in ADHF. The minimal 24-hour response at the current dose is therefore expected: the patient may still be below the NKCC2 threshold at 40 mg IV in the setting of bowel wall edema-related distribution changes and the clinical ADHF state. Escalating to 100 mg IV twice daily is the pharmacodynamically rational and evidence-supported next step before considering sequential blockade.

Option A: Option A is incorrect: the patient has not received the DOSE trial-supported high dose and the ceiling has not been confirmed; adding metolazone before exhausting the appropriate furosemide dose escalation is premature and exposes the patient to unnecessary combination risks.
Option B: Option B is incorrect: furosemide tachyphylaxis in the sense of receptor desensitization is not an established mechanism for the observed poor response; the issue is inadequate dosing, not receptor insensitivity; bumetanide at 1 mg IV is approximately equivalent to 40 mg furosemide and would not provide the required dose escalation.
Option C: Option C is incorrect: the DOSE trial does not establish that clinical response characteristically appears on day 2–3; premature dose escalation causing AKI was not a finding of the DOSE trial — the trial specifically showed high-dose was renal-safe; maintaining the current underdose for another 48 hours is inconsistent with DOSE trial evidence.
Option D: Option D is incorrect: OAT-mediated secretion occurs at the proximal tubule via basolateral transporters and is not dependent on intestinal blood flow; bowel wall edema affects oral drug absorption, which is why IV administration was chosen; continuous infusion was compared with intermittent bolus in the DOSE trial and showed no significant difference in primary endpoints.

6. A 48-year-old man with bipolar I disorder has been stable on lithium carbonate for three years with consistent trough levels of 0.8 mEq/L. His primary care physician starts hydrochlorothiazide (HCTZ) 25 mg daily for mild lower extremity edema. Two weeks later he presents with confusion, coarse tremor, ataxia, and a serum lithium level of 2.1 mEq/L. His serum creatinine is unchanged from baseline. Which of the following best explains the mechanism by which HCTZ elevated lithium to toxic levels, and identifies the preferred diuretic alternative when diuresis is genuinely required in a lithium-treated patient?

A) HCTZ elevated lithium by inhibiting P-glycoprotein-mediated lithium efflux across the blood-brain barrier, increasing CNS lithium exposure without changing plasma levels; the preferred alternative is furosemide, which does not affect blood-brain barrier transporters and is safe to use with lithium at any dose
B) Lithium is freely filtered at the glomerulus and reabsorbed in the proximal convoluted tubule (PCT) via NHE3 and other sodium-permeable transporters alongside sodium; HCTZ-induced NCC blockade in the DCT produces natriuresis and volume contraction that activates compensatory NHE3 upregulation in the PCT, causing the kidney to reabsorb sodium — and lithium — more avidly; plasma lithium can double or triple within days; the preferred alternative when diuresis is required is amiloride, which blocks ENaC in the collecting duct without generating the compensatory PCT sodium avidity that drives lithium reabsorption
C) HCTZ elevated lithium by inducing hepatic CYP2D6, the isoenzyme responsible for lithium glucuronidation; impaired hepatic metabolism reduced lithium clearance and caused plasma accumulation; the preferred alternative is furosemide, which is not a CYP2D6 inducer and does not affect lithium hepatic elimination
D) HCTZ elevated lithium by reducing GFR through afferent arteriolar vasoconstriction, decreasing the filtered lithium load and raising plasma lithium through reduced tubular delivery; the preferred alternative is spironolactone, which increases GFR through aldosterone-mediated efferent arteriolar dilation, restoring lithium clearance
E) HCTZ elevated lithium by directly blocking OAT-mediated lithium secretion into the tubular lumen in the PCT; because lithium reaches the urine primarily by OAT secretion (not filtration), HCTZ-induced OAT competition reduced lithium excretion and raised plasma levels; the preferred alternative is torsemide, which does not compete with lithium at OAT sites because of its hepatic rather than renal elimination

ANSWER: B

Rationale:

Lithium is a small, uncharged monovalent cation that is freely filtered at the glomerulus — it is not protein-bound — and is reabsorbed in the proximal convoluted tubule by NHE3 and other sodium-permeable transporters that cannot discriminate between sodium and lithium. When HCTZ blocks NCC in the DCT, sustained natriuresis produces volume contraction that activates the renin-angiotensin system. Angiotensin II upregulates NHE3-mediated sodium (and lithium) reabsorption in the PCT as a compensatory response to sodium depletion. The kidney reabsorbs both sodium and lithium more avidly, reducing lithium clearance and raising plasma lithium concentration. This effect can be dramatic: thiazides have been documented to double or triple plasma lithium within days of initiation, converting a therapeutic trough to a toxic level without any change in the lithium dose. The stable creatinine in this patient confirms the mechanism is pharmacokinetic (altered lithium renal handling), not prerenal AKI-driven. The preferred diuretic when one is genuinely required in a lithium-treated patient is amiloride: it blocks ENaC in the collecting duct, producing modest sodium loss without generating the degree of PCT sodium avidity that drives lithium reabsorption, and it does not significantly increase lithium plasma concentrations.

Option A: Option A is incorrect: HCTZ does not inhibit blood-brain barrier P-glycoprotein; the plasma lithium level of 2.1 mEq/L confirms that systemic (not just CNS) lithium is elevated; furosemide is not safe at any dose with lithium — it raises lithium levels through the same PCT sodium-avidity mechanism, though typically to a lesser degree than thiazides.
Option C: Option C is incorrect: lithium is not hepatically glucuronidated; lithium is eliminated unchanged by the kidney without significant hepatic metabolism; HCTZ does not induce CYP2D6; this mechanism is entirely fictitious.
Option D: Option D is incorrect: HCTZ does not cause significant afferent arteriolar vasoconstriction or meaningful GFR reduction in a patient with normal creatinine; the mechanism is PCT lithium reabsorption from sodium avidity, not reduced filtered lithium load; spironolactone does not increase GFR through efferent arteriolar dilation.
Option E: Option E is incorrect: lithium is not secreted by OAT into the tubular lumen; it is freely filtered (not protein-bound, not OAT-dependent) and reabsorbed in the PCT; OAT competition is not the mechanism of lithium retention.

7. A 61-year-old woman with HFrEF and atrial fibrillation is on furosemide 80 mg daily and digoxin 0.125 mg daily. She presents with nausea, loss of appetite, and yellow-tinged vision for three days. Her heart rate is 36 bpm with a 2:1 atrioventricular (AV) block on the ECG. Serum digoxin level is 1.0 ng/mL (reference range 0.5–0.9 ng/mL for heart failure). Serum potassium is 2.6 mEq/L and serum magnesium is 1.3 mg/dL. A student asks why toxicity has developed at a digoxin level barely above the upper limit of the therapeutic range, and why measuring the digoxin level alone is insufficient to assess toxicity risk in diuretic-treated patients. Which of the following best explains the pharmacodynamic mechanism and the limitation of the digoxin level as the sole toxicity marker?

A) The digoxin level of 1.0 ng/mL is within normal limits for rate control in atrial fibrillation (therapeutic range 1.0–2.0 ng/mL for rate control); the toxicity reflects furosemide directly inhibiting the sodium-calcium exchanger (NCX1) in cardiomyocytes, increasing intracellular calcium independently of Na/K-ATPase; digoxin level is irrelevant to this furosemide-mediated toxicity
B) The toxicity reflects furosemide-induced volume depletion reducing digoxin's volume of distribution and concentrating it in the myocardium; the plasma digoxin level underestimates myocardial drug exposure because digoxin is sequestered in muscle tissue following volume contraction; measuring tissue digoxin levels rather than plasma levels would reveal true myocardial toxicity
C) The digoxin level is within the standard therapeutic range (0.5–1.2 ng/mL); the toxicity is caused by furosemide-induced metabolic alkalosis shifting potassium intracellularly, reducing extracellular potassium and increasing the transmembrane resting potential of cardiomyocytes; the digoxin level is insufficient as a sole toxicity marker because alkalosis-driven membrane potential changes are not reflected in plasma drug concentrations
D) Potassium and magnesium are physiological competitors of digoxin at the extracellular face of the Na/K-ATPase alpha-subunit; furosemide-induced hypokalemia reduces this competitive antagonism, increasing digoxin's binding affinity and pump occupancy at the same plasma drug concentration and lowering the effective toxic threshold; concurrently, furosemide-induced hypomagnesemia depletes intracellular magnesium, disinhibiting ROMK channels and producing obligatory potassium secretion that perpetuates and deepens the hypokalemia; measuring the digoxin level alone is insufficient because it does not capture the pharmacodynamic sensitization produced by electrolyte depletion — the same plasma level has widely different toxic potential depending on the concurrent potassium and magnesium concentrations
E) The toxicity reflects furosemide inducing hepatic CYP3A4, which paradoxically reduces digoxin metabolism by saturating the enzyme with furosemide metabolites; the accumulated digoxin reaches toxic myocardial concentrations despite a near-normal plasma level because plasma levels do not reflect hepatic drug accumulation; measuring the digoxin level is insufficient because hepatic accumulation is not detectable by standard plasma assays

ANSWER: D

Rationale:

This case requires understanding that digoxin toxicity is a pharmacodynamic phenomenon that depends critically on the ionic environment at the Na/K-ATPase binding site, not only on the plasma drug concentration. Digoxin inhibits the alpha-subunit of the Na/K-ATPase by binding to its extracellular potassium-binding site. Extracellular potassium competes with digoxin for this site — when potassium is normal, competitive antagonism limits digoxin's pump occupancy at any given plasma concentration. When furosemide depletes potassium to 2.6 mEq/L, this competitive antagonism is substantially reduced, and digoxin binds the Na/K-ATPase more avidly, occupying a greater fraction of pump molecules at the same plasma drug concentration of 1.0 ng/mL. The effective pharmacodynamic potency of digoxin increases without the plasma level changing. Concurrently, furosemide-induced magnesiuria (from abolition of the TAL lumen-positive potential) has depleted intracellular magnesium to 1.3 mg/dL. Intracellular magnesium normally blocks ROMK channels in collecting duct principal cells, limiting potassium secretion. With magnesium depleted, ROMK channels remain constitutively open and potassium continues to be secreted obligatorily, perpetuating and deepening the hypokalemia regardless of potassium supplementation — until magnesium is corrected. This self-reinforcing cycle (hypomagnesemia → ROMK disinhibition → sustained hypokalemia → ↑digoxin binding) explains why toxicity developed at a plasma level of 1.0 ng/mL. The digoxin level alone is therefore insufficient as a toxicity risk assessment: it captures the pharmacokinetic dimension but not the pharmacodynamic sensitization produced by concurrent electrolyte depletion.

Option A: Option A is incorrect: the therapeutic range for atrial fibrillation rate control is not 1.0–2.0 ng/mL — current guidelines recommend lower target levels (0.5–0.9 ng/mL for HFrEF); furosemide does not directly inhibit NCX1 in cardiomyocytes; this mechanism is fictitious.
Option B: Option B is incorrect: volume depletion does not meaningfully alter digoxin's volume of distribution or concentrate it in the myocardium; digoxin has a large volume of distribution (approximately 7 L/kg) due to extensive tissue binding that is not altered by modest extracellular fluid volume changes.
Option C: Option C is incorrect: while furosemide can cause metabolic alkalosis, the mechanism of digoxin sensitization in this case is electrolyte depletion-driven reduction in competitive antagonism at the Na/K-ATPase, not alkalosis-driven membrane potential changes; and the digoxin level of 1.0 ng/mL slightly exceeds the HFrEF target range.
Option E: Option E is incorrect: furosemide is not a CYP3A4 inducer; digoxin is not significantly metabolized by CYP3A4 — it is predominantly renally eliminated as unchanged drug; hepatic accumulation is not the explanation for toxicity at this plasma level.

8. A 70-year-old man with nephrotic syndrome (24-hour urine protein 11.2 g, serum albumin 1.8 g/dL) and preserved renal function (GFR 72 mL/min/1.73 m²) has been escalated to oral furosemide 160 mg twice daily with minimal diuretic response over five days. He has no concurrent CKD, no NSAID use, and is compliant with his medications. Which of the following best identifies the dominant pharmacokinetic barrier to oral furosemide efficacy in this patient and the most appropriate management pivot?

A) In nephrotic syndrome with preserved renal function, the dominant pharmacokinetic barrier is intraluminal albumin delivered to the tubular fluid through the leaky glomerular filtration barrier; furosemide — approximately 98% protein-bound in plasma — readily re-binds to this intraluminal albumin in the proximal tubular lumen, reducing the free drug concentration available to inhibit NKCC2 at its luminal binding site; additionally, oral bioavailability is further impaired by bowel wall edema from hypoalbuminemia; the appropriate pivot is to switch to high-dose IV furosemide to overcome absorption impairment and to administer sufficiently high doses to ensure that enough free drug remains after intraluminal albumin binding to reach threshold NKCC2 inhibition
B) The dominant barrier is OAT competition from accumulated uremic organic anions in the plasma competing for OAT1 and OAT3 binding sites on the proximal tubular basolateral membrane; because this patient has a GFR of 72 mL/min, OAT competition is the primary reason furosemide cannot achieve adequate luminal concentration; the appropriate pivot is to add probenecid to block OAT-mediated reabsorption of uremic anions and free up OAT sites for furosemide secretion
C) The dominant barrier is furosemide's increased volume of distribution in nephrotic syndrome; hypoalbuminemia increases the free plasma fraction, which distributes furosemide into peripheral tissues rather than delivering it to the kidney; the appropriate pivot is to administer furosemide as a slow infusion over 24 hours rather than bolus doses, allowing steady-state plasma concentration to equilibrate with the peripheral compartment
D) The dominant barrier is reduced glomerular filtration of furosemide in nephrotic syndrome; the massive proteinuria reduces oncotic pressure in the Bowman's capsule, paradoxically increasing GFR and diluting the filtered furosemide concentration below NKCC2 threshold; the appropriate pivot is to administer a protein supplement infusion before each furosemide dose to restore oncotic pressure and normalize the filtered drug concentration
E) The dominant barrier is furosemide inactivation by nephrotic-range proteinuria in the systemic circulation; urinary proteins that reach the plasma through tubuloglomerular back-leak bind furosemide before it can be secreted by OAT into the tubular lumen; the appropriate pivot is to administer albumin infusion before furosemide to saturate all circulating protein-binding sites and deliver more free furosemide to OAT transporters

ANSWER: A

Rationale:

In nephrotic syndrome with preserved renal function, the pharmacokinetic barrier to furosemide efficacy differs from CKD. There is no significant OAT competition from uremic anions (GFR is 72 mL/min and no CKD is present), but two other barriers operate. First, the glomerular filtration barrier is severely disrupted by nephrotic-range proteinuria, allowing large quantities of albumin to escape into the tubular filtrate. Furosemide is approximately 98% protein-bound in plasma; when it is secreted via OAT into the tubular lumen and encounters this intraluminal albumin, it re-binds avidly, reducing the free (pharmacologically active) drug concentration at the NKCC2 luminal binding site below the inhibitory threshold. This intraluminal albumin-binding mechanism is the dominant pharmacokinetic barrier in pure nephrotic syndrome without CKD. Second, severe hypoalbuminemia causes bowel wall edema that impairs oral drug absorption, making the already-variable oral bioavailability of furosemide (10–90%) even more unreliable. The appropriate management pivot is to switch to IV furosemide, which bypasses the absorption barrier, and to use sufficiently high doses to ensure that even after intraluminal albumin binds a fraction of the drug, enough free furosemide remains to achieve NKCC2 threshold concentrations. In practice, very high IV doses (often 200–400 mg per dose) may be required.

Option B: Option B is incorrect: OAT competition from uremic anions is a CKD mechanism and is not significant at a GFR of 72 mL/min; probenecid blocks OAT-mediated secretion of both furosemide and urate and would reduce furosemide tubular delivery, not increase it — the opposite of the intended effect.
Option C: Option C is incorrect: increased volume of distribution from hypoalbuminemia does not redirect furosemide to peripheral tissues in a way that reduces renal delivery; in fact, increased free plasma fraction from reduced protein binding can enhance OAT-mediated secretion; the peripheral distribution mechanism described does not account for the observed resistance.
Option D: Option D is incorrect: furosemide is not filtered at the glomerulus — it is approximately 98% protein-bound and reaches NKCC2 via OAT secretion; oncotic pressure changes in the Bowman's capsule do not affect furosemide delivery; increased GFR from reduced oncotic pressure is not a recognized mechanism of furosemide resistance.
Option E: Option E is incorrect: urinary proteins do not back-leak into the systemic circulation to bind furosemide before OAT secretion; the protein-binding problem is intraluminal (within the tubular lumen after secretion), not systemic; albumin infusion before furosemide has been studied and does not consistently improve natriuresis in nephrotic syndrome, though it is sometimes used empirically.

9. A 54-year-old woman with known primary hyperparathyroidism (managed conservatively) was started on HCTZ 25 mg daily three weeks ago for stage 1 hypertension. She now presents with fatigue, constipation, polydipsia, and mild confusion. Her serum calcium is 12.9 mg/dL (up from 10.8 mg/dL three months ago). Serum PTH is elevated at 142 pg/mL (normal <65). Which of the following best explains HCTZ's contribution to this patient's worsening hypercalcemia and identifies the correct sequence of acute management?

A) HCTZ contributed to hypercalcemia by blocking NKCC2 in the TAL and abolishing the lumen-positive potential that normally drives paracellular calcium secretion into the tubular lumen; with paracellular calcium secretion eliminated, urinary calcium excretion falls and serum calcium rises; correct management is to immediately start furosemide to restore the lumen-positive potential and paracellular calcium secretion before administering IV saline
B) HCTZ contributed to hypercalcemia by directly stimulating PTH secretion through a calcium-sensing receptor-independent mechanism in the parathyroid gland; the NCC blockade signal is transmitted hormonally to the parathyroid via a renal tubular-parathyroid axis; correct management is to discontinue HCTZ and administer cinacalcet to suppress the HCTZ-stimulated PTH excess
C) HCTZ contributed to hypercalcemia through its calcium-sparing mechanism: NCC blockade in the DCT reduces intracellular sodium, enhancing NCX1 basolateral activity and increasing TRPV5-mediated apical calcium entry, reducing urinary calcium excretion; in this patient with primary hyperparathyroidism, HCTZ's reduction in renal calcium excretion removed a critical safety valve for managing PTH-driven calcium input from bone and gut; correct acute management requires stopping HCTZ immediately, then administering aggressive IV normal saline to restore volume and promote calciuresis, and adding furosemide only after volume is repleted to sustain urinary calcium excretion through its calciuric mechanism
D) HCTZ is not contributing to the hypercalcemia because thiazides reduce urinary calcium excretion only modestly (5–10%), which is insufficient to raise serum calcium above normal in the presence of intact parathyroid hormone suppression; the worsening hypercalcemia reflects disease progression of the primary hyperparathyroidism independent of HCTZ; the correct management is to refer for parathyroidectomy without changing the HCTZ
E) HCTZ contributed to hypercalcemia by blocking TRPV5 channels directly in the DCT, preventing active calcium reabsorption and causing hypercalciuria that overwhelmed the parathyroid gland's ability to retain calcium; the worsening hypercalcemia reflects a paradoxical PTH-driven overcorrection; correct management is to continue HCTZ to maintain the calciuric effect that prevents nephrocalcinosis

ANSWER: C

Rationale:

This case requires integrating the pharmacological calcium-sparing mechanism of HCTZ with the pathophysiology of primary hyperparathyroidism. HCTZ blocks NCC in the DCT, reducing intracellular sodium in DCT cells. The lower intracellular sodium enhances basolateral NCX1 activity and drives increased TRPV5-mediated apical calcium entry, reducing urinary calcium excretion by 30–50%. In a healthy patient, this modest calcium retention is clinically useful (stone prevention). In a patient with primary hyperparathyroidism, elevated PTH continuously drives calcium input — from bone resorption and increased intestinal absorption — and the kidneys' ability to excrete this excess calcium is a critical compensatory mechanism. HCTZ's pharmacological reduction of urinary calcium eliminates this renal safety valve, allowing serum calcium to rise from 10.8 to 12.9 mg/dL over three weeks. The acute management sequence is critical: first, stop HCTZ immediately to remove the pharmacological calcium retention mechanism. Second, administer aggressive IV normal saline: hypercalcemia induces nephrogenic diabetes insipidus through AQP2 suppression, causing volume depletion that further reduces GFR and limits calciuresis; IV saline restores GFR and tubular flow, promoting passive calciuresis. Third, add furosemide only after volume is restored: furosemide abolishes the TAL lumen-positive potential, eliminating paracellular calcium reabsorption and sustaining urinary calcium excretion; administering furosemide before volume repletion in a volume-depleted patient would cause further volume contraction, reduce GFR, and worsen hypercalcemia.

Option A: Option A is incorrect: HCTZ blocks NCC in the DCT, not NKCC2 in the TAL; the lumen-positive potential mechanism is specific to loop diuretics; the management sequence is wrong — furosemide before IV saline in a volume-depleted patient would worsen hypercalcemia.
Option B: Option B is incorrect: HCTZ does not stimulate PTH secretion through a renal tubular-parathyroid signaling axis; the calcium-sparing effect is a direct tubular transport consequence of NCC blockade; cinacalcet would address PTH excess but does not correct the pharmacological contribution of HCTZ or the volume depletion.
Option D: Option D is incorrect: thiazide-mediated reduction in urinary calcium is not modest at 5–10% — it is 30–50% — and this magnitude of reduction is clinically significant in a patient with primary hyperparathyroidism whose serum calcium depends on adequate renal calcium excretion; the worsening represents a pharmacological contribution that can be partially reversed by stopping HCTZ.
Option E: Option E is incorrect: HCTZ does not block TRPV5 directly — it enhances TRPV5-mediated calcium entry by reducing intracellular sodium; the mechanism is increased calcium reabsorption, not decreased; the clinical consequence is reduced urinary calcium and worsened hypercalcemia, not hypercalciuria.

10. A 66-year-old man with HFrEF and stage 4 CKD (GFR 28 mL/min/1.73 m²) is admitted with volume overload. He has been escalated over 48 hours to IV furosemide 160 mg twice daily and net urine output remains only 600 mL above intake. Creatinine is stable, potassium is 3.8 mEq/L, and magnesium is 1.8 mg/dL. No nephrotoxins are present. His cardiologist considers adding metolazone. A medical student asks what must be confirmed before metolazone is added and what monitoring is mandatory once sequential blockade begins. Which of the following best answers both questions?

A) Before adding metolazone, the team must confirm the patient has no sulfonamide allergy, since both furosemide and metolazone contain sulfonamide groups and additive hypersensitivity reactions are the primary risk of combination therapy; after starting metolazone, the mandatory monitoring is serum chloride and urine anion gap to detect metabolic alkalosis developing from the combination
B) Before adding metolazone, the team must switch furosemide to oral administration, since metolazone is only effective when the upstream loop diuretic is given orally; after starting metolazone, the mandatory monitoring parameter is urine osmolality to confirm NKCC2 blockade is sustaining the medullary concentration gradient disruption required for metolazone to act in the DCT
C) Before adding metolazone, the team must confirm that the patient's serum potassium is above 4.5 mEq/L, since sequential nephron blockade predictably causes severe hyperkalemia from ENaC blockade by metolazone in the collecting duct; after starting metolazone, the mandatory monitoring is serum potassium every six hours for the first 48 hours to detect this expected hyperkalemia
D) Before adding metolazone, the team must rule out primary aldosteronism as the cause of loop diuretic resistance; if aldosterone is elevated, spironolactone should be added instead of metolazone; if aldosterone is normal, metolazone is appropriate; after starting metolazone, monitoring serum sodium is the single most important parameter because hyponatremia is the most frequent and dangerous complication of sequential nephron blockade
E) Before adding metolazone, the team should confirm that the furosemide dose is genuinely above the NKCC2 threshold — evidenced by some natriuretic response at 160 mg IV twice daily — to ensure that blocking the distal nephron will intercept sodium that has actually escaped the TAL rather than adding metolazone when upstream blockade is incomplete; once sequential blockade begins, potassium, magnesium, and creatinine must be checked within 24–48 hours because the combined natriuresis can produce rapid hypokalemia from ROMK-mediated secretion, hypomagnesemia from increased TAL washout, and AKI from volume depletion

ANSWER: E

Rationale:

This question requires integrating the pharmacodynamic rationale for sequential blockade with the specific monitoring requirements of the combination. Before adding metolazone, the most important clinical confirmation is that furosemide is producing meaningful upstream NKCC2 blockade — evidenced by some natriuretic response at the current dose — so that metolazone will intercept sodium genuinely escaping the TAL rather than being added when the primary drug is itself below threshold. In this patient, 600 mL net output above intake confirms that some natriuresis is occurring at 160 mg IV twice daily, suggesting the NKCC2 threshold has been reached and that distal compensatory reabsorption is the limiting factor. Metolazone is therefore appropriately targeted. If no response whatsoever were present (suggesting below-threshold dosing), further furosemide escalation would be indicated before metolazone is added. Once sequential blockade is initiated, three mandatory monitoring parameters must be checked within 24–48 hours: potassium (because combined NKCC2 and NCC blockade dramatically increases sodium delivery to the collecting duct, driving intense ROMK-mediated potassium secretion), magnesium (because the increased tubular flow and washout from the amplified natriuresis further impairs paracellular magnesium reabsorption in the TAL, worsening existing magnesium depletion), and creatinine (because rapid, large-volume natriuresis can deplete intravascular volume faster than transcapillary refill, reducing GFR acutely). Daily weights are essential to track fluid balance.

Option A: Option A is incorrect: while furosemide contains a sulfonamide group, sulfonamide allergy assessment is not the primary pre-metolazone clinical checkpoint; additive hypersensitivity from sulfonamide group overlap is not a well-established clinical concern sufficient to prioritize over pharmacodynamic threshold confirmation; serum chloride and urine anion gap are not the mandatory monitoring priorities after sequential blockade.
Option B: Option B is incorrect: metolazone does not require oral furosemide administration as a prerequisite; IV furosemide is the preferred route in hospitalized patients with ADHF; metolazone's NCC blockade in the DCT operates independently of the route by which furosemide is administered.
Option C: Option C is incorrect: metolazone blocks NCC in the DCT, not ENaC in the collecting duct — it does not cause hyperkalemia; the expected electrolyte complication of sequential blockade is severe hypokalemia (not hyperkalemia) from increased collecting duct sodium delivery and ROMK secretion.
Option D: Option D is incorrect: ruling out primary aldosteronism before every metolazone decision is not a standard clinical checkpoint for loop-resistant volume overload in HFrEF; hyponatremia is not the most frequent or most dangerous complication of sequential nephron blockade — hypokalemia and AKI are the primary concerns requiring close monitoring.

11. A 63-year-old man with HFrEF was switched eight months ago from furosemide to torsemide 20 mg daily because of erratic furosemide responses. He has been well-controlled since, maintaining target dry weight. He now develops alcoholic hepatitis over three weeks, with rising bilirubin, falling albumin, and a prolonged prothrombin time. His cardiologist notes that despite no change in the torsemide dose, the patient's urine output has increased dramatically, he has lost 4.2 kg over ten days, and his creatinine has risen from 1.5 to 2.6 mg/dL, suggesting over-diuresis. Which of the following best explains the pharmacokinetic mechanism of this unexpected change and identifies the appropriate management response?

A) Alcoholic hepatitis reduced albumin synthesis, increasing the free plasma fraction of torsemide; higher free drug concentrations accelerated OAT-mediated secretion of torsemide into the tubular lumen, raising luminal drug concentrations above the NKCC2 ceiling; the appropriate management is to discontinue torsemide entirely and substitute furosemide infusion, which does not undergo OAT-mediated secretion and therefore avoids this albumin-loss effect
B) Torsemide is approximately 80% hepatically metabolized via CYP2C9; alcoholic hepatitis impairs CYP2C9 activity, reducing torsemide clearance and extending its half-life beyond the usual 3–4 hours; with each successive daily dose administered before the prior dose is cleared, drug accumulates progressively; the rising plasma and luminal torsemide concentrations deliver supratherapeutic NKCC2 blockade, producing excessive natriuresis, volume depletion, and the observed creatinine rise; the appropriate management is to substantially reduce the torsemide dose or switch to furosemide, whose predominantly renal elimination is relatively preserved despite the hepatic impairment
C) Alcoholic hepatitis caused portal hypertension that increased renal blood flow through hepatorenal vasodilation, raising GFR and tubular fluid delivery to NKCC2; the same torsemide dose now produces greater natriuresis because more sodium is delivered to NKCC2 per unit time; the appropriate management is to reduce torsemide to 10 mg daily and add spironolactone to counteract the aldosterone excess from hepatic impairment
D) The over-diuresis reflects furosemide contamination of the torsemide prescription; furosemide has a shorter half-life (1.5–2 hours) than torsemide, and contamination introduced erratic peaks of NKCC2 blockade; the appropriate management is to verify the dispensed medication, confirm purity, and resume torsemide at the same dose once the correct preparation is confirmed
E) Alcoholic hepatitis reduced hepatic albumin synthesis, causing hypoalbuminemia that increased the free fraction of torsemide in plasma; the larger free fraction enhanced glomerular filtration of torsemide (since filtration depends on free drug concentration), raising tubular lumen concentrations; the appropriate management is to administer albumin infusions to restore protein binding and reduce the filterable free fraction back to pre-hepatitis levels

ANSWER: B

Rationale:

The pharmacokinetic advantage that made torsemide preferable over furosemide in this patient — approximately 80% hepatic metabolism via CYP2C9 making clearance independent of GFR — has become a liability now that hepatic function is impaired. Alcoholic hepatitis reduces hepatic CYP2C9 activity, as evidenced by the prolonged prothrombin time (reflecting impaired clotting factor synthesis, a marker of hepatic synthetic function that correlates with metabolic enzyme activity). With CYP2C9 activity reduced, torsemide is metabolized more slowly, its half-life extends beyond the usual 3–4 hours, and each daily dose is not fully cleared before the next is administered. Progressive drug accumulation raises the plasma torsemide concentration, increases OAT-mediated tubular secretion and luminal drug concentration, and delivers supratherapeutic NKCC2 blockade that generates excessive natriuresis. The volume depletion from over-diuresis reduces intravascular volume, decreases renal perfusion, and explains the creatinine rise from 1.5 to 2.6 mg/dL. The appropriate response is to substantially reduce the torsemide dose — or switch to furosemide, whose clearance is predominantly renal via OAT-mediated tubular secretion; even with CKD impairing furosemide clearance to some degree, the hepatic CYP2C9 impairment destabilizing torsemide does not significantly affect furosemide's renal elimination pathway, making furosemide the more predictable choice in this clinical context. This case illustrates the reciprocal vulnerabilities: furosemide is unreliable in renal impairment; torsemide is unreliable in hepatic impairment.

Option A: Option A is incorrect: furosemide does undergo OAT-mediated secretion — OAT-dependent tubular secretion is the route by which all loop diuretics reach NKCC2; furosemide's advantage over torsemide in hepatic impairment is its renal clearance pathway, not an absence of OAT dependence.
Option C: Option C is incorrect: alcoholic hepatitis typically reduces renal blood flow through hepatorenal physiology (vasoconstriction, not vasodilation); hepatic impairment does not increase GFR through portal hypertension-mediated vasodilation; the creatinine rise confirms reduced rather than increased GFR.
Option D: Option D is incorrect: prescription contamination is not a rational clinical explanation for a predictable pharmacokinetic effect of hepatic impairment on a drug with established CYP2C9 metabolism; the mechanism is well understood and does not require medication verification.
Option E: Option E is incorrect: torsemide is highly protein-bound (approximately 99%) and is not meaningfully filtered at the glomerulus; it reaches the tubular lumen via OAT-mediated secretion, not filtration; albumin infusions would not reduce torsemide's luminal concentration by reducing a filterable free fraction.